Richard Scolyer reflects on being both a patient and a co-author in a newly published Nature Medicine study
Richard Scolyer, Senior Staff Specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital, shared a post on X about a paper he co-authored with colleagues published in Nature Medicine:
“I am very proud to be part of the amazing team of researchers, scientists and clinicians who are all co-authors of the important research publication just released in Nature Medicine. The paper documents changes in my brain tumour and blood before and after I received neoadjuvant systemic combination immunotherapy treatment, which occurred in 2023.
Everyone involved, including lead authors Georgina Long and Helen Rizos, used their expertise, knowledge and creative intellect to generate this important data just released.
Whilst the paper deals with the data from just one patient (me), ultimately a clinical trial of a large group of patients needs to be conducted to determine whether or not neoadjuvant (pretreatment) combination immunotherapy is clinically effective in (a subgroup of) brain cancer patients. I hope such a trial begins in the not too distant future.
Congratulations to everyone who has contributed to this research. What a fantastic achievement!
But this is only the beginning and much more research is required to improve treatment and outcomes and ultimately save lives.”
“Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma”
Authors: Georgina Long, Elena Shklovskaya, Laveniya Satgunaseelan, Richard Scolyer, James Wilmott, Helen Rizos et al.
More posts featuring Richard Scolyer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023